Home›Research›Compare›CJC-1295 (without DAC) vs Mod GRF 1-29
Peptide ComparisonCJC-1295 (without DAC) vs Mod GRF 1-29
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC-1295
Half-life: ~30 minutes
446 providers listed
Mod GRF 1-29
CJC-1295 no DAC
Half-life: ~30 minutes
15 providers listed
Mod GRF 1-29 carries stronger published evidence (RCT, 2 key studies) than CJC-1295 (without DAC) (Review, 1); both are research compounds.
CJC-1295 (without DAC)
Evidence
Half-life
~30 minutes
Mod GRF 1-29
Evidence
Half-life
~30 minutes
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Mod GRF 1-29 |
| More provider options (446 vs 15) | CJC-1295 (without DAC) |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
Mod GRF 1-29
CJC-1295 (without DAC)
Mod GRF 1-29
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About Mod GRF 1-29
Modified GHRH analog; binds GHRH receptors with improved stability to produce physiological GH pulses when combined with a GHRP
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceMod GRF 1-29
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
Mod GRF 1-29
Ipamorelin
Research suggests Ipamorelin and Mod GRF 1-29 may produce enhanced growth hormone pulse effects when combined. Ipamorelin acts via ghrelin receptors (GHSR) while Mod GRF 1-29 acts via GHRH receptors — distinct pathways that research suggests may amplify GH secretion when activated together.
CJC-1295 (without DAC)
Mod GRF 1-29
Where to source these peptides
CJC-1295 (without DAC)
446 listed
Browse directory →
Providers offeringMod GRF 1-29
15 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs Mod GRF 1-29 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/mod-grf-1-29